Welcome to the e-CCO Library!

P342: Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chao C.-Y.*1,2, Lemieux C.1, Afif W.1, Bitton A.1, Wild G.1, Bessissow T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P342: Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
Year: 2022
Source: ECCO'22
Authors: Wong, S.Y.(1);Helmus, D.(2);Marlow, L.(3);Martinez Pazos, V.(2);Brann, S.(3);Wellens, J.(4);Kedia, S.(5);Mak , J.W.Y.(6);Bergemalm, D.(7);Argollo, M.(8);Zaltman, C.(9);Steinwurz, F.(10);Rubin, D.(11);Allez, M.(12);Halfvarson, J.(7);Abreu, M.T.(13);Lindsay, J.(14);Dutta, U.(15);Silverberg, M.S.(16);Ng, S.C.(6);Ahuja, V.(5);Watanabe, K.(17);Vermeire, S.(18);Colombel, J.F.(2);Satsangi, J.(19);
Created: Friday, 11 February 2022, 3:52 PM
P342: Treatment experience of perianal fistulising Crohn's disease: a systematic literature review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McKay, C.(1)*;Pacis, S.(2);Bolzani, A.(2);Geransar, P.(3);Panés, J.(4);
Created: Friday, 14 July 2023, 11:05 AM
P342: Tryptophan as a biomarker for the course of IBD and anti-TNF α response
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Brandt*1, S. Nikolaus2, N. Al-Massad2, J. Bethge2, D. Schuldt2, S. Szymczak3, F. Thieme4, G. H. Waetzig5, M. Krawczak3, R. Junker4, P. Rosenstiel6, S. Schreiber2

Created: Friday, 22 February 2019, 9:49 AM
P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Akyüz, A. Ormeci, N. Namazova, M. Guzel, A. Abbasgoulizadeh, L. Tahincioğlu, S. Alaskarlı, E. Gürel, E. Bilgin, A. Atasoy, B. Cavus, K. Demir, F. Besısık, S. Kaymakoğlu

Created: Thursday, 30 January 2020, 10:12 AM
P343: Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Bouhnik, Y.(2);Laharie, D.(3);Elgharabawy, Y.(4);
Created: Friday, 11 February 2022, 3:52 PM
P343: Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, B. Sands2, J-F. Colombel2, C. Gasink3, R. Patel4, D. Jacobstein5, L-L. Gao5, S. Ghosh6, S. Targan7, W. De Villiers8, S. B. Hanauer9, P. Rutgeerts10, B. Feagan11

Created: Friday, 22 February 2019, 9:41 AM
P343: Eosinophilic inflammation as an indicator of the activity of the course of Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Babayeva-Sadigova, G.(1)*;Asadova, G.(2);Quliyev , F.(2);Makhmudov , U.(3);Ismayilova , K.(1);Samedova , T.(2);Hasanova , A.(4);Mirzazada , O.(4);Mahammadaliyeva , M.(4);Abdulzada , C.(4);Musayev, C.(5);Iskenderov , N.(6);
Created: Friday, 14 July 2023, 11:05 AM
P343: Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

O'Connor A.*1, Gracie D.1, Hamlin J.1, Selinger C.1, Ford A.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P343: Levels of the anticoagulant and anti-inflammatory protein S (PROS1) in patients with inflammatory bowel disease (IBD) relationship with disease activity, IBD disease patterns, and C4-binding protein (C4BP)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Sambuelli1*, P. Chavero1, G. de Larrañaga2, A. Errasti3, S. Peres2, L. Tessone3, S. Negreira2, N. Silvia1, M. Bellicoso1, S. Huernos1, S. Goncalves1, P. Tirado1, E.A. Carrera Silva4, C. Rothlin5

Created: Thursday, 21 February 2019, 9:14 AM
P343: Maintenance of deep remission in Crohn’s disease after switching from anti–TNF to ustekinumab.
Year: 2021
Source: ECCO'21 Virtual
Authors: Mantzaris, G.(1);Vraka, M.(1);Beka, H.(1);Georgiadi, T.(1);Albani, F.(1);Veretanos, C.(1);Mountaki, K.(1);Trikola, A.(1);Archavlis, E.(1);Christidou, A.(1);Manolakis, A.(1);Viazis, N.(1);Karampekos, G.(1);Philippidis, G.(1);Hatzievangelinou, C.(1);Tsatsa, A.(1);Georgiadou, A.(1);Panagopoulou, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P343: The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease and the relationship with biochemical markers of disease activity
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Diederen1, D. Hoekman*1, T. Hummel2, T. de Meij3, B. Koot1, M. Tabbers1, A. Vlieger4, A. Kindermann1, M. Benninga1

Created: Friday, 22 February 2019, 9:49 AM
P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Truyens1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, P. Hindryckx1,3, T. Lobaton Ortega1,3

Created: Thursday, 30 January 2020, 10:12 AM
P344: Diverting ileostomy in Inflammatory Bowel Disease's surgery: the real clinical cost analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ascari, F.(1)*;Barugola, G.(2);Ruffo, G.(2);
Created: Friday, 14 July 2023, 11:05 AM
P344: Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Hanzel, J.(1,2);Strik, A.(2);Gecse, K.(2);D'Haens, G.(2);Dreesen, E.(3,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P344: Epidemiology of clostridium difficile infections in IBD over two decades
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Moens1,2*, B. Verstockt1,2, K. Machiels2, P. Bossuyt3, A. Verdonck4, K. Lagrou4, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P344: Non-adherence to medical therapy is associated with hospitalisations and the development of active disease in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Severs*1, H. H. Fidder1, M.-J. Mangen2, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

Created: Friday, 22 February 2019, 9:49 AM
P344: Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ungaro*1, M. Fenster1, C. Dimopoulos1, A. Patel2, P. Deepak3, G. Syal4, A. Yarur5, R. Hirten1, G. Christophi3, A. Khatiwada3, B. Lin5, J-F. Colombel1, C. Ha4, R. Weisshof6, P. Beniwal-Patel5, B. Cohen1, J. Pekow6

Created: Friday, 22 February 2019, 9:41 AM
P344: Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gubatan J.M., Mitsuhashi S., Longhi M.S., Zenlea T., Rosenberg L., Robson S., Moss A.

Created: Wednesday, 20 February 2019, 10:36 AM
P344: What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis
Year: 2022
Source: ECCO'22
Authors: Zarchi, R.(1);Elgressy, A.(2);Ben-Horin, S.(2);Kopylov, U.(2);
Created: Friday, 11 February 2022, 3:52 PM